| Popis: |
Background: Thalassemia is a genetic disorder caused by an imbalance between α or β globin chain production resulting in an ineffective synthesis of hemoglobin chains. Treatment involves regular blood transfusions that cause iron build-up and tissue damage in organs causing, cardiomyopathy, diabetes, hyperthyroidism, interstitial lung fibrosis, cirrhosis, etc.Aims: To assess the efficacy of iron chelators: daily oral deferasirox vs combination of daily oral deferasirox + intermittent injectable deferoxamine in reducing serum ferritin level in thalassemia major patient. The main outcome was a decrease in serum ferritin after 1 year. Methods: They are randomly allocated into two groups. Both groups will take periodically blood transfusions but one group will receive oral deferasirox (group A) daily alone and group B will receive Deferasirox along with injectable deferoxamine by intravenous route only during periodic blood transfusions. In the B group along with it post-transfusion injectable deferoxamine will be given over four hours diluted in normal saline. Every 2 monthly serum ferritin level was done for 12 months.Results: Group A (n=30) with s ferritin mean± SD at base 7581.6±2389.7 and at 1 year 5288.5 ±2226.0, a decrease of 25.8%; and in Group B (n=30) with Mean± SD at base 9096.2± 3063.6 and 4698.4 ±2689.9 at 1 year, a decrease of 43.2% which is significant (p= |
